FDA's withholding of the PRV was contrary to law because no drug product containing phenobarbital sodium was 'previously approved'
The IND application supports the next phase of development of SBO-154
SPARC to receive 55% equity in Tiller Therapeutics
SPARC will be eligible to receive an upfront payment, milestone payments and royalty on sales, in addition to 10% equity in Visiox
SPARC will pay Biomodifying a percentage of payments received for sublicenses of the licensed IP
The trial met its pre-specified primary endpoint, demonstrating that PDP-716 dosed once daily is equivalent to Alphagan P 0.1% dosed 3 times a day
Subscribe To Our Newsletter & Stay Updated
